NCT05087992 - A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

October 23, 2023

Study Completion Date

November 14, 2023

Conditions

Gastrointestinal Cancer, Metastatic

Interventions

DRUG

BI 905711

DRUG

FOLFIRI

DRUG

Bevacizumab

Trial Locations (5)

UZ Leuven, Leuven

The University of Texas MD Anderson Cancer Center, Houston

HOP la Milétrie, Poitiers

Beijing Cancer Hospital, Beijing

National Cancer Center Hospital East, Chiba, Kashiwa